The p53 codon 72 polymorphism and risk of high-grade cervical intraepithelial neoplasia

Koushik, Anita; Ghosh, Anirban; Duarte-Franco, Eliane; Forest, Pierre; Voyer, Hélène; Matlashewski, Greg; Coutlée, François; Franco, Eduardo L.

doi:10.1016/j.cdp.2005.06.007

Cited by 37 publications

(45 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The BCCR study is a case-control study, designed to investigate the role of biomarkers as predictors of different CIN grades. 22 Cases consisted of women with an abnormal screening Pap smear who were referred to one of five colposcopy clinics of the collaborating hospitals of the McGill University Health Centre (MUHC) and the Centre hospitalier de l'Universit e de Montr eal (CHUM). Only women who underwent a colposcopy-guided cervical biopsy were invited to participate as cases in the study.…”

Section: Selection Of Casesmentioning

confidence: 99%

See 1 more Smart Citation

Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16

Louvanto

Franco

Ramanakumar

et al. 2014

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Methylation of human papillomavirus (HPV) and host genes may predict cervical cancer risk. We examined the methylation status of selected sites in HPV16 and human genes in DNA extracted from exfoliated cervical cell samples of 244 women harboring HPV16-positive cancer or cervical intraepithelial neoplasia (CIN) or negative for intraepithelial lesions or malignancy (NILM). We quantified the methylation of CpG sites in the HPV16 L1 gene (CpG 6367 and 6389) and in the human genes EPB41L3 (CpG 438, 427, 425) and LMX1 (CpG 260, 262, 266, 274) following bisulfite treatment and pyrosequencing. Receiver operating characteristic (ROC) curves were used to analyze the diagnostic utility of methylation level for the different sites and for a joint predictor score. Methylation in all sites significantly increased with lesion severity (p < 0.0001). Area under the curve (AUC) was highest among the CIN2/3 vs. cancer ranging from 0.786 to 0.853 among the different sites. Site-specific methylation levels strongly discriminated CIN2/3 from NILM/CIN1 and cancer from CIN2/3 (range of odds ratios [OR]: 3.69-12.76, range of lower 95% confidence bounds: 1.03-4.01). When methylation levels were mutually adjusted for each other EPB41L3 was the only independent predictor of CIN2/3 vs. NILM/CIN1 contrasts (OR 5 9.94, 95%CI: 2.46-40.27). High methylation levels of viral and host genes are common among precancerous and cancer lesions and can serve as independent risk biomarkers. Methylation of host genes LMX1 and EPB41L3 and of the viral HPV16 L1 sites has the potential to distinguish among precancerous lesions and to distinguish the latter from invasive disease.Cervical cancer is the third most common cancer worldwide and is caused by persistent infection with oncogenic strains of the human papillomavirus (HPV).1,2 Approximately 80% of women will be infected with HPV in their lifetime but only a small percentage will develop cervical cancer.3 It would be advantageous to discover a method to differentiate between an HPV infection that would likely persist and lead to cancer and one that would spontaneously disappear.Papanicolaou (Pap) cytology is currently the screening method of choice for cervical cancer in most countries; however change is underway and HPV DNA testing has been combined with Pap testing in the US as the preferred screening method, while in Canada and some European countries pilot programs that feature screening with HPV DNA followed by triage with cytology have started.4,5 Although HPV-DNA testing has been shown to be particularly sensitive, there are concerns regarding its low specificity. 6 For women who have

show abstract

Section: Selection Of Casesmentioning

confidence: 99%

“…22 Extracted DNA was amplified for HPV detection using PGMY primers and typed with the Linear Array assay (Roche Molecular systems, CA).…”

Section: Cervical Specimen Processingmentioning

confidence: 99%

Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16

Louvanto

Franco

Ramanakumar

et al. 2014

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, we explored the role of IGF variables on HPV infection, independent of the risk of cervical cancer precursors, by examining the association of plasma levels of IGF-I and IGFBP-3 with HPV infection among the controls. study, which has previously been described in detail (29). Cases were recruited from among women presenting at the colposcopy clinics of the collaborating hospitals of the McGill University Health Centre and the Centre Hospitalier de l'Université de Montréal for a suspected high-grade lesion.…”

Section: Introductionmentioning

confidence: 99%

Insulin-like Growth Factor-I and Risk of High-Grade Cervical Intraepithelial Neoplasia

Schaffer

Koushik²,

Trottier³

et al. 2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

Self Cite

View full text Add to dashboard Cite

Insulin-like growth factors (IGF) and their binding proteins (IGFBP) have been implicated in the risk of several epithelial or glandular tumors, including prostate cancer, breast cancer, and colon cancer. Cervical cancer, which is also of epithelial origin, has been shown to overexpress receptors for IGF-I, and plasma levels of IGF-I have been positively associated with cervical cancer precursors in one epidemiologic study. In this case-control study, we investigated plasma levels of IGF-I and IGFBP-3 in relation to the risk of histologically confirmed high-grade cervical intraepithelial neoplasia (HGCIN) and the risk of human papillomavirus (HPV) infection. Included in this analysis were 329 cases and 621 controls recruited from clinics affiliated with two Montréal-area hospital centers. We observed a reduced risk of HGCIN for increasing levels of IGF-I, with an adjusted odds ratio (OR) of 0.40 (95% confidence interval, 0.19-0.87) for the highest quartile relative to the lowest quartile of IGF-I. No association was observed between IGFBP-3 levels and HGCIN. Among controls, IGF-I was associated with a decreased risk of being positive for HPV-16 or HPV-18, with an adjusted odds ratio of 0.20 (95% confidence interval, 0.05-0.87) for the highest quartile relative to the lowest quartile of IGF-I. There was no association observed between IGFBP-3 levels and HPV infection status. IGF-I -mediated effects seemed to predominate among women <30 years of age. In contrast to the previously reported study, our results suggest that levels of IGF-I in young women may be inversely associated with HGCIN, a precursor to cervical cancer. (Cancer Epidemiol Biomarkers Prev 2007;16(4):716 -22)

show abstract

“…Overall, 265 genital specimens collected from 95 women and 170 men participating in four studies described elsewhere (8,11,14,16) were selected on the basis of previous testing of PGMY-generated amplicons with the cross-reacting HPV-33/35/52/58 probe and with conventional HPV-52 typing methods (see below). Anal swabs were collected in Preservcyt (Cytyc Corporation, Boxborough, MA) from 170 men in the HIPVIRG cohort with low-grade anal intraepithelial neoplasia (AIN) (n ϭ 74), high-grade AIN (n ϭ 56), AIN of unknown grade (n ϭ 4), or no AIN (n ϭ 36), and DNA was extracted as previously described (8).…”

mentioning

confidence: 99%

“…Cervical samples were collected and processed as previously described from 53 women recruited in The Canadian Women's HIV Study with a normal cytology (n ϭ 47) or low-grade squamous intraepithelial lesion (n ϭ 6) (11,16). Cervical Cytobrush samples collected from 26 women participating in the Biomarkers of Cervical Cancer Risk case-control study (14) and from 16 Inuit women participating in a cohort study in northern Quebec were processed as described for anal samples above. Each participant had given written informed consent for HPV testing.…”

mentioning

confidence: 99%

Confirmatory Real-Time PCR Assay for Human Papillomavirus (HPV) Type 52 Infection in Anogenital Specimens Screened for HPV Infection with the Linear Array HPV Genotyping Test

et al. 2007

View full text Add to dashboard Cite

A novel real-time PCR assay for detection of human papillomavirus type 52 (HPV-52) DNA (RT-52) was evaluated on 265 anogenital samples. RT-52 had a sensitivity of 98.4% and a specificity of 100% compared to conventional HPV-52 typing assays, including hybridization of PGMY products with an HPV-52-specific probe and PCR sequencing of HPV-52 E6.The detection of high-risk human papillomavirus (HPV) types in genital specimens has now been approved in several countries for the triage of women with a cytological diagnosis of atypical squamous cells of undetermined significance (ASCUS) and for the primary screening for cervical cancer for women aged 30 years and above as an adjunct to cytology (18). HPV DNA genotyping has proven useful in the study of the natural history and transmission of HPV infection (9,15). Genotyping assays will be instrumental in assessing the impact of HPV vaccination on the risk of acquisition and on the distribution of individual HPV types in a population. Moreover, HPV genotyping could identify HPVinfected women at greater risk for high-grade cervical intraepithelial neoplasia or cancer (2, 13, 15).The Linear Array HPV genotyping test (LA-HPV) from Roche Molecular Systems is approved by Health Canada for HPV genotyping. LA-HPV identifies 36 genotypes by hybridization on a linear array of PGMY-generated amplicons with 34 type-specific probes for , two probes for two subtypes of HPV-82, and one probe that cross-reacts with . A sample is thus considered positive for HPV-52 when it reacts with the HPV-52-cross-reactive probe but not with the HPV-33, -35, or -58 type-specific individual probes. However, LA-HPV cannot establish the presence of HPV-52 DNA in a sample reacting with the HPV-33/35/52/58-cross-reactive probe and with at least one of the HPV type-specific probe for HPV-33, -35, or -58. If these samples are considered positive for HPV-52, the prevalence of HPV-52 will be overestimated, and if they are considered negative, HPV-52 prevalence may be underestimated.HPV-52 is the seventh most frequently detected high-risk type in invasive cervical cancer worldwide (5) and causes 8.8% of low-grade and 2.5% of high-grade squamous intraepithelial lesions (4). It is thus imperative in epidemiological studies to be able to determine if HPV-52 is truly present in samples reacting with the HPV-52-cross-reactive probe and containing another type reacting with that probe. We present here the results of the validation of a novel real-time PCR assay for the rapid confirmation of HPV-52 infection in specimens positive with the HPV-52 cross-reacting probe in the LA-HPV test.Clinical specimens. Overall, 265 genital specimens collected from 95 women and 170 men participating in four studies described elsewhere (8,11,14,16) were selected on the basis of previous testing of PGMY-generated amplicons with the cross-reacting HPV-33/35/52/58 probe and with conventional HPV-52 typing methods (see below). Anal swabs were collected in Preservcyt (Cytyc Corporation, Boxborough, MA) from 170 men in the HIPVIRG cohort ...

show abstract

The p53 codon 72 polymorphism and risk of high-grade cervical intraepithelial neoplasia

Cited by 37 publications

References 47 publications

Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16

Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16

Insulin-like Growth Factor-I and Risk of High-Grade Cervical Intraepithelial Neoplasia

Confirmatory Real-Time PCR Assay for Human Papillomavirus (HPV) Type 52 Infection in Anogenital Specimens Screened for HPV Infection with the Linear Array HPV Genotyping Test

Contact Info

Product

Resources

About